Atossa Therapeutics Inc (NASDAQ: ATOS)’s stock price has increased by 4.59 compared to its previous closing price of 0.86. However, the company has seen a 12.22% increase in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-02 that SEATTLE, June 2, 2025 /PRNewswire/ — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that Dr. Steven Quay, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 7:35 a.m.
Is It Worth Investing in Atossa Therapeutics Inc (NASDAQ: ATOS) Right Now?
Additionally, the 36-month beta value for ATOS is 0.91. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ATOS is 129.12M and currently, short sellers hold a 5.74% ratio of that float. The average trading volume of ATOS on June 26, 2025 was 713.86K shares.
ATOS’s Market Performance
ATOS stock saw an increase of 12.22% in the past week, with a monthly gain of 7.37% and a quarterly increase of 29.45%. The volatility ratio for the week is 5.28%, and the volatility levels for the last 30 days are 6.43% for Atossa Therapeutics Inc (ATOS). The simple moving average for the last 20 days is 6.74% for ATOS stock, with a simple moving average of -11.14% for the last 200 days.
Analysts’ Opinion of ATOS
Many brokerage firms have already submitted their reports for ATOS stocks, with Maxim Group repeating the rating for ATOS by listing it as a “Buy.” The predicted price for ATOS in the upcoming period, according to Maxim Group is $2 based on the research report published on January 26, 2018 of the previous year 2018.
ATOS Trading at 8.82% from the 50-Day Moving Average
After a stumble in the market that brought ATOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.70% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATOS starting from QUAY STEVEN C, who purchase 11,239 shares at the price of $0.88 back on May 21 ’25. After this action, QUAY STEVEN C now owns 13,898 shares of Atossa Therapeutics Inc, valued at $9,887 using the latest closing price.
Remmel H. Lawrence, the Director of Atossa Therapeutics Inc, purchase 10,000 shares at $0.70 during a trade that took place back on Mar 26 ’25, which means that Remmel H. Lawrence is holding 10,257 shares at $7,000 based on the most recent closing price.
Stock Fundamentals for ATOS
The total capital return value is set at -0.32. Equity return is now at value -34.87, with -32.56 for asset returns.
Currently, EBITDA for the company is -25.49 million with net debt to EBITDA at 3.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.67.
Conclusion
In conclusion, Atossa Therapeutics Inc (ATOS) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
